Limited Value of the Multi-Biomarker Disease Activity Assay Compared to the Routine Assessment of Patient Index Data 3 (RAPID3) Score in the Prognosis of Important Clinical Outcomes in Rheumatoid Arthritis: Comment on the Article by Fleischmann et al and Accompanying Editorial by Davis
- PMID: 27992686
- DOI: 10.1002/art.40022
Limited Value of the Multi-Biomarker Disease Activity Assay Compared to the Routine Assessment of Patient Index Data 3 (RAPID3) Score in the Prognosis of Important Clinical Outcomes in Rheumatoid Arthritis: Comment on the Article by Fleischmann et al and Accompanying Editorial by Davis
Comment in
-
Reply.Arthritis Rheumatol. 2017 Apr;69(4):867-868. doi: 10.1002/art.40021. Epub 2017 Feb 28. Arthritis Rheumatol. 2017. PMID: 27992708 No abstract available.
Comment on
-
Brief Report: Estimating Disease Activity Using Multi-Biomarker Disease Activity Scores in Rheumatoid Arthritis Patients Treated With Abatacept or Adalimumab.Arthritis Rheumatol. 2016 Sep;68(9):2083-9. doi: 10.1002/art.39714. Arthritis Rheumatol. 2016. PMID: 27111089 Free PMC article. Clinical Trial.
-
Editorial: The Multi-Biomarker Disease Activity Test for Rheumatoid Arthritis: Is It a Valid Measure of Disease Activity?Arthritis Rheumatol. 2016 Sep;68(9):2061-6. doi: 10.1002/art.39716. Arthritis Rheumatol. 2016. PMID: 27111349 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
